PharmaLundensis AB Logo

PharmaLundensis AB

Develops treatments for heavy metal toxicity and serious respiratory illnesses.

PHAL | SPGR

Overview

Corporate Details

ISIN(s):
SE0003359710 (+5 more)
LEI:
54930082I88D5N3GQ506
Country:
Sweden
Address:
Scheelevägen 22, 223 63 Lund
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

PharmaLundensis AB is a pharmaceutical research company that develops treatments for diseases with significant unmet needs. The company's primary project is PHAL-501, a drug designed to bind and excrete heavy metals like mercury, lead, and cadmium from the body. PHAL-501 is intended to act within the intestine, capturing toxins before they are absorbed into the bloodstream, thus offering a potentially safe and effective treatment for heavy metal toxicity. In addition to this focus, the company is also involved in developing therapies for serious respiratory illnesses, such as chronic obstructive pulmonary disease (COPD).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PharmaLundensis AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PharmaLundensis AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PharmaLundensis AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Tord Staffan Håkan Skogvall Other Buy 2,337 1,986.45 SEK
2025-01-17 SkåneÖrnen AB Other Buy 121,700 96,143.00 SEK
2025-01-17 Tord Staffan Håkan Skogvall Other Buy 10,958 7,999.34 SEK
2024-10-14 SkåneÖrnen AB Other Buy 49,370 19,748.00 SEK
2024-10-09 Tord Staffan Håkan Skogvall Other Buy 27,936 10,336.32 SEK
2024-09-26 SkåneÖrnen AB Other Buy 63,000 29,610.00 SEK
2024-09-20 Bo Wennergren Other Buy 60,000 27,600.00 SEK

Peer Companies

1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain
IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea
394800
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America
FDMT
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America
ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea
174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea
203400
Abivax S.A. Logo
Biotech developing oral drugs for chronic inflammatory diseases like colitis and Crohn's.
United States of America
ABVX
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea
298380
Absci Corp Logo
A generative AI drug creation platform for designing and optimizing biologic therapeutics.
United States of America
ABSI
ABVC BIOPHARMA, INC. Logo
Develops plant-based drugs and medical devices for CNS, oncology, and ophthalmic disorders.
United States of America
ABVC

Talk to a Data Expert

Have a question? We'll get back to you promptly.